Casdin Capital as of Dec. 31, 2015
Portfolio Holdings for Casdin Capital
Casdin Capital holds 27 positions in its portfolio as reported in the December 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Blueprint Medicines (BPMC) | 9.6 | $11M | 413k | 26.34 | |
| Illumina (ILMN) | 8.5 | $9.6M | 50k | 191.93 | |
| Sage Therapeutics (SAGE) | 7.4 | $8.3M | 143k | 58.30 | |
| Bluebird Bio (BLUE) | 6.8 | $7.7M | 120k | 64.22 | |
| Loxo Oncology | 6.3 | $7.2M | 252k | 28.45 | |
| Cytomx Therapeutics (CTMX) | 5.9 | $6.7M | 321k | 20.87 | |
| Agios Pharmaceuticals (AGIO) | 5.8 | $6.6M | 102k | 65.00 | |
| Spark Therapeutics | 5.8 | $6.6M | 145k | 45.31 | |
| Myokardia | 5.2 | $5.9M | 404k | 14.66 | |
| Genomic Health | 5.1 | $5.8M | 165k | 35.20 | |
| Alnylam Pharmaceuticals (ALNY) | 5.0 | $5.6M | 60k | 94.13 | |
| Epizyme | 4.7 | $5.3M | 333k | 16.02 | |
| Voyager Therapeutics (VYGR) | 4.6 | $5.2M | 237k | 21.90 | |
| Biogen Idec (BIIB) | 2.4 | $2.8M | 9.0k | 306.33 | |
| Foundation Medicine | 2.4 | $2.7M | 130k | 21.06 | |
| GenMark Diagnostics | 2.1 | $2.4M | 310k | 7.76 | |
| Bristol Myers Squibb (BMY) | 2.0 | $2.2M | 32k | 68.80 | |
| Global Blood Therapeutics In | 1.9 | $2.1M | 65k | 32.32 | |
| Invitae (NVTAQ) | 1.8 | $2.1M | 250k | 8.21 | |
| Kite Pharma | 1.6 | $1.8M | 30k | 61.63 | |
| Dex (DXCM) | 1.2 | $1.4M | 17k | 81.88 | |
| OraSure Technologies (OSUR) | 1.0 | $1.1M | 170k | 6.44 | |
| Oxford Immunotec Global | 0.8 | $863k | 75k | 11.51 | |
| Juno Therapeutics | 0.7 | $769k | 18k | 43.94 | |
| Atara Biotherapeutics (ATRA) | 0.6 | $660k | 25k | 26.40 | |
| Medidata Solutions | 0.4 | $493k | 10k | 49.30 | |
| Trovagene | 0.3 | $378k | 70k | 5.40 |
